

The problem

- > 90% of drug candidates *fail* before reaching the market → traditional animal models and conventional 2D cell cultures *poorly* predict human responses.
- Result: billions of € / year lost, long development timelines, and unsafe or ineffective therapies progressing through the drug development pipeline.



Pharmaceutical and biotech companies *urgently need* more predictive, scalable, and human-relevant *preclinical models*

Why now?

Several global trends are accelerating demand:

- Regulatory agencies are increasingly encouraging *alternatives* to animal testing
- Precision medicine requires *patient-specific* human models
- AI-driven drug discovery needs high-quality biological validation systems
- The global organoids market is projected to surpass billions in value within the next decade: € 12-15B by 2030

OrganoStemTech is positioned at the intersection of regenerative medicine, biotech, and next-generation preclinical testing

Business Model

OrganoStemTech operates through *multiple* revenue streams:

1. Direct sales of organoids and 2D and 3D in vitro platforms
2. Custom disease modeling services
3. Preclinical drug testing partnerships
4. Collaborative R&D with pharma and biotech companies

Our Vision

Our vision is to become a leading European provider of human-relevant preclinical platforms that accelerate safer, faster, and more efficient therapeutic development.

We believe the future of drug discovery should be:

Human-based. Predictive. Personalized.

OrganoStemTech develops advanced human iPSC-derived *organoids* and *organ-on-chip platforms* that replicate human tissue physiology with unprecedented accuracy.

We provide:

- ★ Intestinal and cerebral organoids (customized and ready-to-use)
- ★ 2D and 3D *in vitro* disease models derived from organoids
- ★ Organ-on-chip systems for dynamic and physiologically relevant testing
- ★ Preclinical drug screening platforms for pharma, biotech, and academic research

Our technology enables faster, more predictive, and ethically responsible drug development while reducing dependence on animal testing

Our Solution

What make Us Different?

- ▶ Human-relevant biology using iPSC-derived tissues
- ▶ Scalable and customizable organoid production
- ▶ Integration with microfluidic organ-on-chip systems
- ▶ Patient-specific disease modeling capabilities
- ▶ Applications across pharma, toxicology, oncology, neurology, and GI diseases

Target Market



Pharmaceutical companies



Biotechnology startups



Academic and translational research centers



Contract Research Organizations

Investment need

OrganoStemTech is currently seeking strategic support, partnerships, and early-stage investment to:

- ▶ Set up laboratory operations
- ▶ Expand iPSC and organoid production capacity
- ▶ Advance proprietary organ-on-chip technologies
- ▶ Accelerate commercial partnerships